title: CEA and CA19.9 as early predictors of progression in advanced/metastatic colorectal cancer patients receiving oxaliplatin-based chemotherapy and bevacizumab.
abstract: We evaluated the changes of the tumor markers CEA and CA19.9 as early predictors of progression in metastatic colorectal cancer (mCRC) patients participating in a clinical study and receiving chemotherapy and bevacizumab (Bev). Seventy-two patients had high baseline CEA or CA19.9 serum levels. By ROC analyses, the areas under the curves were 0.83 for variable CEA cutoff values for distinguishing progressive disease (PD) versus stable disease (SD)/partial remission (PR)/complete remission (CR), and 0.80 for variable CA19.9 cutoff values for distinguishing PD versus SD/PR/CR. Rises in CEA and CA19.9 may early signal the occurrence of progression in mCRC patients receiving chemotherapy and Bev.
authors.affiliation: Medical Oncology Unit, University of Siena, Siena, Italy. r.petrioli@ao-siena.toscana.it
authors.forename: Roberto
authors.initials: R
authors.lastname: Petrioli
authors.forename: Antonella
authors.initials: A
authors.lastname: Licchetta
authors.forename: Giandomenico
authors.initials: G
authors.lastname: Roviello
authors.forename: Alessandra
authors.initials: A
authors.lastname: Pascucci
authors.forename: Edoardo
authors.initials: E
authors.lastname: Francini
authors.forename: Gianluca
authors.initials: G
authors.lastname: Bargagli
authors.forename: Raffaele
authors.initials: R
authors.lastname: Conca
authors.forename: Salvatora Tindara
authors.initials: ST
authors.lastname: Miano
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Marzocca
authors.forename: Guido
authors.initials: G
authors.lastname: Francini
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D018395:CA-19-9 Antigen / Q000097:blood*; D000069287:Capecitabine; D002272:Carcinoembryonic Antigen / Q000097:blood*; D015179:Colorectal Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D018450:Disease Progression; D005260:Female; D005472:Fluorouracil / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000627:therapeutic use*; D000077150:Oxaliplatin; D011379:Prognosis
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018395:CA-19-9 Antigen; D002272:Carcinoembryonic Antigen; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D003841:Deoxycytidine; D000068258:Bevacizumab; D000069287:Capecitabine; D005472:Fluorouracil